Biovia
BIOVIA, a brand of Dassault Systèmes SE, provides enterprise scientific software on the 3DEXPERIENCE platform — including molecular modeling, lab informatics, materials simulation, and AI-driven drug discovery — for pharmaceutical, biotech, consumer packaged goods, chemicals, and mobility customers.
- Company typePrivate
- Founded2001
- HeadquartersSan Diego, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
What Biovia does
BIOVIA is the scientific software brand of Dassault Systèmes SE, the French multinational publicly traded on Euronext Paris (DSY.PA). Originally founded in 2001 and acquired by Dassault Systèmes in 2016, BIOVIA provides a portfolio of enterprise scientific applications built on the 3DEXPERIENCE platform. The portfolio spans six disciplines — Biosciences, Laboratory Informatics, Materials Science & Engineering, Scientific Informatics, Regulatory Management, and Quality Management — with core products including BIOVIA Discovery Studio (molecular modeling and simulation), BIOVIA ONE Lab (LIMS/ELN/instrument integration), BIOVIA Pipeline Pilot (scientific data science and ML), BIOVIA Materials Studio (in-silico materials design), BIOVIA Scientific AI (generative AI and Virtual Advisors), BIOVIA Generative Therapeutics Design, BIOVIA Formulation Design, BIOVIA Discoverant (manufacturing analytics), BIOVIA Quality, and BIOVIA Regulatory, supported by COSMO-RS thermodynamic modeling.
The platform's central technical premise is a unified scientific data model connecting research, development, manufacturing, and quality, enabling Virtual Twin Experiences that simulate and predict real-world behavior of molecules, formulations, materials, and processes before physical experimentation. Recent AI capabilities include generative AI for novel molecular and materials design, LLMs powering Virtual Advisors for formulation and lab workflows, and integration of AlphaFold protein-structure models via the OpenFold consortium, with accelerated AI inference delivered through a flagship partnership with NVIDIA.
BIOVIA generates revenue primarily through enterprise software licensing and subscriptions, supplemented by contract research and professional services, with a freemium entry point (Discovery Studio Visualizer) feeding enterprise deployments and discounted academic licensing available to institutions. It sells through direct enterprise sales globally, targeting large pharmaceutical and biotech companies, consumer packaged goods firms, chemicals and materials companies, and transportation/mobility industrials, with disclosed enterprise customers including Pfizer, AstraZeneca, Amgen, Gilead, Sanofi, Bayer, Hovione, Aboca, L'Oréal, Procter & Gamble, Unilever, Dow Chemical, Airbus, General Motors, and Tesla.
Biovia firmographics
Firmographics- Name
- Biovia
- Legal name
- Dassault Systèmes SE
- Website
- https://3dsbiovia.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BIOVIA, a brand of Dassault Systèmes SE, provides enterprise scientific software on the 3DEXPERIENCE platform — including molecular modeling, lab informatics, materials simulation, and AI-driven drug discovery — for pharmaceutical, biotech, consumer packaged goods, chemicals, and mobility customers.
- Ownership category
- akta.pro rank
Biovia industry classification
Industry- Product category
- Scientific R&D Software
- NAICS
- Software Publishers (51321)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL)
Keywords
Where Biovia is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Biovia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Enterprise Software Licenses and Subscriptions: BIOVIA generates primary revenue through enterprise software licensing and subscription fees. Products include Discovery Studio (with free visualizer and paid full version), Materials Studio, Pipeline Pilot, ONE Lab, and other specialized scientific software. Academic institutions can access discounted licensing options with institutional pricing. The model is primarily subscription-based for enterprise deployments on the 3DEXPERIENCE platform.
- Contract Research and Professional Services: BIOVIA offers contract research services and professional services offerings to augment software deployments. This includes implementation services, training, and specialized scientific consulting for pharmaceutical and materials science applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free Visualizer for Discovery Studio |
| Subscription | Annual | Academic Licensing |
| Subscription | Annual | Enterprise Commercial Licensing |
Distribution channels3 records
Marketing channels9 records
Biovia product offering
Product offeringCore offering
BIOVIA develops and sells enterprise scientific software on the 3DEXPERIENCE platform for life sciences, materials science, and drug discovery. Core products include molecular modeling and simulation (Discovery Studio), lab informatics (ONE Lab), scientific data science (Pipeline Pilot), materials simulation (Materials Studio), and AI-powered scientific research (Scientific AI). The portfolio also covers formulation design, manufacturing analytics, quality and regulatory management for pharmaceutical, biotech, consumer packaged goods, and industrial customers.
Product overview
BIOVIA is a comprehensive scientific software portfolio from Dassault Systèmes offering a platform-plus-modules architecture built on the 3DEXPERIENCE platform. The core platform, 3DEXPERIENCE BIOVIA, provides a unified data model connecting specialized solutions including BIOVIA Discovery Studio (molecular modeling and simulation), BIOVIA ONE Lab (comprehensive lab informatics beyond traditional LIMS), BIOVIA Pipeline Pilot (scientific data science and ML), BIOVIA Materials Studio (materials design), and BIOVIA Scientific AI (generative AI and LLMs for scientific R&D). Key modules include BIOVIA Generative Therapeutics Design for AI-powered molecule creation, BIOVIA Formulation Design for formulation workflows, BIOVIA Insight for analytics, and BIOVIA Discoverant for manufacturing analytics. The portfolio is organized across six interconnected disciplines: Biosciences, Laboratory Informatics, Materials Science & Engineering, Scientific Informatics, Regulatory Management, and Quality Management. The platform enables the 'molecule to manufacturing' approach through Virtual Twin Experiences that connect virtual modeling with real-world experimentation.
Differentiator
Problem solved
Functional benefit
Brands
- BIOVIA Discovery Studio: Molecular modeling and simulation software for drug discovery and biotherapeutic design.
- BIOVIA ONE Lab
- BIOVIA Pipeline Pilot
- BIOVIA Materials Studio
- BIOVIA Scientific AI
- BIOVIA Formulation Design
- BIOVIA Discoverant
- BIOVIA Generative Therapeutics Design
Products and services
- 3DEXPERIENCE BIOVIA Open, collaborative platform providing a unified data model that connects all BIOVIA solutions across the product development lifecycle from research to manufacturing.
- BIOVIA Discovery Studio Simulation Molecular modeling and simulation software for life sciences research and drug discovery, enabling visualization and analysis of molecular structures. Includes a free visualizer version and a paid full license.
- BIOVIA ONE Lab Comprehensive lab informatics suite that goes beyond traditional LIMS, including guided procedure execution, electronic lab notebooks (ELN), instrument and inventory management, and integration with AI analytics.
- BIOVIA Pipeline Pilot Scientific data science and machine learning platform that enables scientists to gather, process, and report experimental data with automated workflows and error checking.
- BIOVIA Materials Studio In-silico design and simulation tool for materials science, allowing researchers to predict and understand properties and behavior of new materials at atomic and molecular levels.
- BIOVIA Scientific AI Specialized AI platform for scientific R&D that integrates generative AI and large language models to deliver actionable insights and accelerate discovery across biological, chemical, and materials systems.
- BIOVIA Generative Therapeutics Design Generative AI solution for creating and optimizing novel therapeutic molecules with desired properties for faster drug development.
- BIOVIA Formulation Design AI-powered formulation development software for the consumer packaged goods (CPG) industry that streamlines formula and recipe development workflows, enhances sustainability, and improves regulatory compliance.
- BIOVIA Insight Advanced analytics application that integrates with ONE Lab for deeper scientific insights and data visualization.
- COSMO-RS Thermodynamic modeling solution for predicting chemical behavior and properties of mixtures.
- BIOVIA Quality AI-based end-to-end digital quality management system ensuring product quality and safety, including management of deviations and CAPAs.
- BIOVIA Regulatory Regulatory management solutions for document authoring with structured content, managing SOPs, and ensuring compliance with global regulatory standards.
- BIOVIA Contract Research Contract research services that augment BIOVIA software deployments, providing specialized scientific expertise and project-based engagements for pharmaceutical and materials science applications.
- BIOVIA Services Offering Professional services including implementation, training, and specialized scientific consulting that accompany BIOVIA software deployments.
Quantifiable outcome
- Scientists saved 1.5 hours per experiment on average using BIOVIA Pipeline Pilot
- +3 more outcomes
Companies that use Biovia
Customer profileNamed customers15 records
Segments4 records
Ideal customer profiles4 records
Biovia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature12 records
Biovia partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- OpenFold ConsortiumcoreDassault Systèmes, through its BIOVIA and MEDIDATA brands, joined the OpenFold consortium in November 2022 to integrate AlphaFold AI models into its 3DEXPERIENCE platform for pharmaceutical research. This partnership advances AI-powered drug discovery capabilities by incorporating state-of-the-art protein structure prediction into BIOVIA's scientific AI portfolio.
- NVIDIAflagshipBIOVIA has a strategic partnership with NVIDIA to combine NVIDIA-accelerated AI inference with BIOVIA's world-class scientific AI and modeling capabilities. This partnership enables the next generation of therapeutics and high-performance materials development within a collaborative 3D universe, providing accelerated AI computation for molecular discovery and simulation workloads.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Biovia competitors and assessment
Company assessmentBroad incumbents
- Sartorius: Global bioprocessing and lab products company with a growing digital/software footprint (including data analytics and bioprocess software). Comparable as a broad incumbent serving biopharma R&D and manufacturing, with partial overlap with BIOVIA's manufacturing analytics (Discoverant) capabilities.
- Revvity (formerly PerkinElmer): Large life sciences and diagnostics company with software, informatics, and lab automation offerings (Signals, ChemDraw, Spotfire). A broad incumbent that overlaps with BIOVIA across lab informatics and scientific data analytics, though spread across a wider portfolio including instruments and reagents.
Direct peers
- IDBS: Life sciences R&D data management and analytics platform (Polar, BioPharma Lifecycle Management) directly comparable to BIOVIA ONE Lab, Pipeline Pilot, and Scientific Informatics. Competes for the same ELN and lab informatics RFPs in biopharma.
- LabVantage: Enterprise LIMS provider with capabilities across laboratory informatics, ELN, and quality management. Direct overlap with BIOVIA's Laboratory Informatics and Quality Management disciplines, particularly in regulated pharma manufacturing environments.
- Veeva Systems: Life sciences cloud platform spanning R&D (Vault RIM, Vault Quality), clinical (Vault CDB, Vault EDC), and commercial. Overlaps with BIOVIA's Regulatory and Quality Management disciplines, and is a leading enterprise software standard across the same pharma customer base.
- Certara: Drug development software and services company spanning biosimulation, regulatory science, and clinical pharmacology. Directly comparable to BIOVIA's Regulatory Management and biosimulation capabilities, and competes for similar pharma R&D and regulatory affairs budgets.
- Dotmatics: Unified scientific informatics platform (including SnapGene, GraphPad Prism, and the Dotmatics enterprise platform) that competes with BIOVIA across ELN, data management, and scientific workflows. Recently backed by Insight Partners with a focus on consolidating life sciences R&D software — direct overlap with BIOVIA's Laboratory Informatics discipline.
- Benchling: Cloud-native life sciences R&D platform offering ELN, LIMS, and molecular biology capabilities directly overlapping with BIOVIA ONE Lab and Scientific Informatics. Targets the same biotech and pharma buyers with a modern, API-first architecture and is one of BIOVIA's most aggressive competitors in net-new enterprise deals.
- Schrödinger: Computational chemistry and molecular simulation platform (LiveDesign) serving pharma and materials science accounts. Directly comparable to BIOVIA Discovery Studio and Materials Studio in physics-based modeling, and increasingly competing in AI-driven molecular design.
- OpenEye (Cadence Molecular Sciences): Molecular modeling and simulation software (OELib, Orion, Cadence) for pharmaceutical research. Directly comparable to BIOVIA Discovery Studio in computational chemistry and structure-based drug design, with growing overlap in cloud-native scientific informatics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biovia social profiles
Digital presenceBiovia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biovia leadership team
Management profileNumber of profiles
Profiles3 records
Biovia subsidiaries and ownership
Company hierarchySubsidiaries1 record
Biovia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biovia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biovia
What does Biovia do?
BIOVIA develops and sells enterprise scientific software on the 3DEXPERIENCE platform for life sciences, materials science, and drug discovery. Core products include molecular modeling and simulation (Discovery Studio), lab informatics (ONE Lab), scientific data science (Pipeline Pilot), materials simulation (Materials Studio), and AI-powered scientific research (Scientific AI). The portfolio also covers formulation design, manufacturing analytics, quality and regulatory management for pharmaceutical, biotech, consumer packaged goods, and industrial customers.
Is Biovia a public or private company?
Biovia is a private company. It is classified as corporate owned and is currently operating.
When was Biovia founded?
Biovia was founded in 2001. It employs 501 to 1,000 people.
Where is Biovia based?
Biovia is headquartered in San Diego, United States, in the North America region.
How does Biovia make money?
Two revenue lines are on record. Enterprise Software Licenses and Subscriptions are the primary driver. The others are contract Research and Professional Services.
Who are Biovia's main competitors?
Broad incumbents on record are Sartorius and Revvity (formerly PerkinElmer). Direct peers are IDBS, LabVantage, Veeva Systems, Certara, Dotmatics, Benchling, Schrödinger and OpenEye (Cadence Molecular Sciences).
Does Biovia have an API?
No public API is recorded for Biovia.
What industry is Biovia in?
Biovia's product category is Scientific R&D Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 51321 and its SIC code is 8731.